- Neuronetics (STIM, Financial) to release Q1 2025 financial results on May 6, 2025.
- The conference call is scheduled at 8:30 a.m. Eastern Time on the same day.
- Webcast available for listen-only mode; telephone registration recommended 10 minutes prior.
Neuronetics, Inc. (STIM), a leader in medical technology specializing in neurohealth disorder treatments, has announced it will release its first quarter 2025 financial and operating results before the market opens on Tuesday, May 6, 2025. The company focuses on improving the quality of life for patients with neurohealth disorders through its innovative solutions.
The earnings results will be followed by a live conference call at 8:30 a.m. Eastern Time on the same day. The call will be accessible in listen-only mode via a webcast at this link. Participants opting to listen via telephone are encouraged to register and join the call 10 minutes before the event begins.
Neuronetics is renowned for its NeuroStar Advanced Therapy for Mental Health, a non-drug, non-invasive treatment that has substantially benefited individuals with conditions such as major depressive disorder (MDD) and obsessive-compulsive disorder. The NeuroStar therapy has delivered over 7.1 million treatments, positioning itself as a leading solution in the TMS treatment space for adults with MDD.
For further details on the therapy and prescribing information, prospective patients and medical professionals can visit neurostar.com. Investor and media inquiries can be directed to the provided contacts for additional information.
